| LLY_10dadbeb | by year end | 2026-10-01 | 2026-12-31 | European regulatory approval for Foundayo (chronic weight management and type 2 diabetes) following a positive CHMP opinion. | This approval is crucial for the anticipated global rollout of Foundayo in major markets in 2027, significantly expanding its international revenue potential. | Ticker | 2026-10-29 | earnings_transcript | LLY (ticker) |
| LLY_48d9403d | later this year | 2026-10-01 | 2026-12-31 | Readout of Foundayo Phase 3 trial in obstructive sleep apnea. | Positive results from this trial could lead to a new, high-value indication for Foundayo, further expanding its utility and market potential beyond its current metabolic indications. | Ticker | 2026-08-05 | earnings_transcript | LLY (ticker) |
| LLY_696cb569 | later this year | 2026-10-01 | 2026-12-31 | U.S. regulatory action (approval/decision) for Foundayo in type 2 diabetes. | This regulatory decision would significantly expand Foundayo's addressable market in the U.S. to include type 2 diabetes, a large and established indication, driving substantial revenue growth. | Ticker | 2026-08-05 | earnings_transcript | LLY (ticker) |
| LLY_cf82d1b5 | a few markets late in 2026 | 2026-10-01 | 2026-12-31 | Launch of Orforglipron in a few international markets (e.g., UAE). | This marks the beginning of the international rollout for oral Orforglipron, contributing to global revenue growth and market penetration. | Ticker | 2026-02-04 | earnings_transcript | LLY (ticker) |
| ABBV_c5da1469 | later this year | 2026-10-01 | 2026-12-31 | US regulatory approval decision for RINVOQ for the treatment of vitiligo. | This approval would mark RINVOQ as the first systemic treatment for vitiligo, significantly expanding its market potential and contributing to the anticipated combined peak sales of $2 billion for vitiligo and alopecia areata indications. | Ticker | 2026-07-31 | earnings_transcript | ABBV (ticker) |
| AMGN_fe4d51bf | We will update you on those discussions as necessary. | 2026-04-24 | 2026-12-31 | Resolution of ongoing discussions with the FDA regarding TABNIO's (avacopan) following a voluntary withdrawal request related to primary endpoint result readjudication. | The outcome will determine the future commercial viability of TABNIO's, impacting Amgen's rare disease portfolio and potentially leading to a re-evaluation of the product's sales trajectory. | Ticker | 2026-02-03 | earnings_transcript | AMGN (ticker) |
| MRK_bcd577c2 | second half of 2026 | 2026-09-01 | 2026-12-31 | Second readout from the ATLAS-UC trial for tulisokibart in moderately to severely active ulcerative colitis. | This readout, combined with the earlier induction study, will form the basis of a regulatory filing, reinforcing confidence in the program's potential and expanding Merck's immunology portfolio. | Ticker | 2026-08-04 | earnings_transcript | MRK (ticker) |
| NVO_71e5b33d | at the end of 2026 | 2026-10-01 | 2026-12-31 | FDA regulatory decision for CagriSema in the U.S. for obesity. | Approval would introduce a new, potentially highly effective obesity treatment, strengthening Novo Nordisk's pipeline and competitive position. | Ticker | 2026-05-06 | earnings_transcript | NVO (ticker) |
| PFE_fe771000 | fourth quarter | 2026-10-01 | 2026-12-31 | First readout of the MEVPRO-1 Phase III study for mevrometostat in post-abiraterone metastatic hormone-resistant prostate cancer. | This pivotal study readout could establish mevrometostat as a breakthrough therapy, delaying resistance to XTANDI and representing a 100% global commercial opportunity for Pfizer. | Ticker | 2026-08-04 | earnings_transcript | PFE (ticker) |
| PFE_0a01f9d3 | later this year at a conference | 2026-09-01 | 2026-12-31 | Presentation of the full data set from the TRANQUILLO 1 and 2 studies for Litfulo in nonsegmental vitiligo. | The full data presentation will provide comprehensive insights into Litfulo's clinically meaningful and statistical efficacy, reinforcing its potential in the vitiligo market. | Ticker | 2026-08-04 | earnings_transcript | PFE (ticker) |
| PFE_a3b83d3f | this year | 2026-09-01 | 2026-12-31 | Start of a pivotal trial investigating NURTEC's use as a treatment for chronic migraine. | This pivotal trial initiation aims to expand NURTEC's label, further strengthening Pfizer's leadership in providing treatment options for migraine patients. | Ticker | 2026-08-04 | earnings_transcript | PFE (ticker) |
| PFE_a1fcc382 | later this year | 2026-09-01 | 2026-12-31 | Release of the clinical trial design for the adjuvant study of atirmociclib in ER-positive breast cancer. | This milestone is crucial for advancing atirmociclib, which is believed to be highly differentiated in the early adjuvant setting due to its tolerability profile, representing a significant opportunity. | Ticker | 2026-08-04 | earnings_transcript | PFE (ticker) |
| REGN_0f639ad7 | November of this year | 2026-11-01 | 2026-11-30 | FDA decision on the New Drug Application (NDA) for cemdisiran, an siRNA targeting C5, in generalized myasthenia gravis (gMG). | Potential approval would introduce a highly differentiated treatment option for gMG patients with a convenient quarterly subcutaneous dosing profile, expanding Regeneron's rare disease portfolio. | Ticker | 2026-07-30 | earnings_transcript | REGN (ticker) |
| REGN_76369989 | before the end of the year | 2026-10-01 | 2026-12-31 | FDA approval of the EYLEA HD prefilled syringe. | This product enhancement is expected to drive even further adoption of EYLEA HD, strengthening its competitive position and contributing to sales growth. | Ticker | 2026-07-30 | earnings_transcript | REGN (ticker) |
| REGN_07f81147 | later this year | 2026-10-01 | 2026-12-31 | Initiation of multiple Phase III studies for olatorepatide in patients with obesity and in patients with obesity and type 2 diabetes. | Marks significant progress in Regeneron's obesity portfolio, positioning the company to enter a high-growth market with a potentially differentiated dual GLP-GIP receptor agonist. | Ticker | 2026-07-30 | earnings_transcript | REGN (ticker) |
| LLY_a24ab55b | December 7th | 2026-12-07 | 2026-12-07 | Lilly Innovation Day. | This event is expected to provide more detailed insights into Lilly's pipeline, potentially revealing new material information about future growth drivers and strategic priorities. | Ticker | 2026-10-29 | earnings_transcript | LLY (ticker) |
| LLY_a075099b | Q1 2027 | 2027-01-01 | 2027-03-31 | U.S. regulatory submission (BLA pathway) for retatrutide. | This submission is a critical step towards bringing the highly efficacious triple agonist, retatrutide, to market, potentially solidifying Lilly's leadership in cardiometabolic health with a drug demonstrating unprecedented weight loss. | Ticker | 2026-10-29 | earnings_transcript | LLY (ticker) |